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Abstract
Simian immunodeficiency viruses of sooty mangabeys (SIVsm) are the source of multiple, successful cross-species
transmissions, having given rise to HIV-2 in humans, SIVmac in rhesus macaques, and SIVstm in stump-tailed macaques.
Cellular assays and phylogenetic comparisons indirectly support a role for TRIM5a, the product of the TRIM5 gene, in
suppressing interspecies transmission and emergence of retroviruses in nature. Here, we investigate the in vivo role of
TRIM5 directly, focusing on transmission of primate immunodeficiency viruses between outbred primate hosts. Specifically,
we retrospectively analyzed experimental cross-species transmission of SIVsm in two cohorts of rhesus macaques and found
a significant effect of TRIM5 genotype on viral replication levels. The effect was especially pronounced in a cohort of animals
infected with SIVsmE543-3, where TRIM5 genotype correlated with approximately 100-fold to 1,000-fold differences in viral
replication levels. Surprisingly, transmission occurred even in individuals bearing restrictive TRIM5 genotypes, resulting in
attenuation of replication rather than an outright block to infection. In cell-culture assays, the same TRIM5 alleles associated
with viral suppression in vivo blocked infectivity of two SIVsm strains, but not the macaque-adapted strain SIVmac239.
Adaptations appeared in the viral capsid in animals with restrictive TRIM5 genotypes, and similar adaptations coincide with
emergence of SIVmac in captive macaques in the 1970s. Thus, host TRIM5 can suppress viral replication in vivo, exerting
selective pressure during the initial stages of cross-species transmission.
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Introduction
The Simian immunodeficiency viruses (SIVs) are widespread
among African primates [1]. However, host and viral phylogenies
are not completely congruent; such a pattern argues against co-
divergence of virus and host lineages since the time of a common,
infected primate ancestor and argues instead that the modern
distribution of SIVs among extant primates resulted, at least in
part, from cross-species transmission events followed by emergence
of new virus/host combinations [2]. The most notable examples
include cross-species transmission of SIV from apes to humans,
which gave rise to HIV-1 and initiated the worldwide AIDS
epidemic, and cross-species transmission of SIV from sooty
mangabeys (SIVsm) to humans, which gave rise to the more
limited HIV-2 epidemic [1,3,4]. In a striking parallel to the
emergence of HIV-1 and HIV-2, SIVsm also jumped into captive
Asian macaques in the United States, resulting in emergence of
SIVmac and outbreaks of AIDS-like disease at several U.S.
National Primate Research Centers in the 1970s [3,5,6]. The
exact time and means by which SIVsm was transmitted to
macaques are unknown, but since isolation of the first SIV strains
from captive macaques in the 1980s, experimental infection of
rhesus macaques with SIV has become the primary animal model
for preclinical research on AIDS vaccines and pathogenesis.
Variation in susceptibility to infection and disease progression in
nonhuman primate models often confounds such studies, and
identifying the sources of variation will lead to more efficient use of
AIDS models. At the same time, genetic variation in nonhuman
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to study the impact of host genetics on cross-species transmission,
adaptation, and emergence of viruses. In the present study, we
establish that allelic variation in the rhesus macaque TRIM5 gene
results in differences in susceptibility to infection and viral
replication in the early stages of cross-species transmission of
SIVsm and that emergence of pathogenic SIVmac in rhesus
macaques required adaptations in the viral capsid protein (CA) to
overcome suppression by two distinct types of TRIM5 allele.
Viral inhibition by TRIM5a, a product of the TRIM5 gene, is
initiated by an interaction between the protein’s B30.2/SPRY
domain and virion capsid-cores released into the target-cell
cytoplasm after viral attachment and entry [7–13]. The target of
TRIM5a involves the N-terminal domain (NTD) of the viral CA
protein [14]. We previously discovered that rhesus macaque
TRIM5 is highly polymorphic, including eight nonsynonymous
polymorphisms tightly clustered in the B30.2/SPRY domain [15].
One of these, a six-nucleotide insertion/deletion, results in a TFP/
Q length polymorphism. When tested against multiple lentiviruses,
TFP
339-341 and Q
339 alleles (TRIM5
TFP and TRIM5
Q) give
different patterns of restriction [16]. An unusual haplotype
encoding a TRIM5-cyclophilin-A chimera (TRIM5CypA) is also
found among rhesus macaques [17,18]. The chimeric TRIM5-
CypA lacks a B30.2/SPRY domain and in its place encodes a
CypA domain derived from a retrotransposed CypA reading
frame inserted in the 39UTR [17–21]. TRIM5CypA restriction of
lentiviral infection involves specific binding to a peptide loop
between helices 4 and 5 of the viral CA (also the binding site for
cellular CypA) [22,23].
Results
Common variants of rhesus TRIM5 can be grouped into three
allelic classes: TRIM5CypA, TRIM5
TFP, and TRIM5
Q (Figure 1)
[16,24]. We established the existence of all six possible genotypes
in a large colony of captive rhesus macaques, using archived
genomic DNA samples from the Genetics Core of the New
England Primate Research Center. In this colony, we observed
frequencies of 46% (TRIM5
TFP/TFP), 36% (TRIM5
TFP/Q), 5%
(TRIM5
TFP/CypA), 10% (TRIM5
Q/Q), 1% (TRIM5
Q/CypA), and 2%
(TRIM5
CypA/CypA). These values indicate allele frequencies in one
particular colony of rhesus macaques; because of differences in
animal husbandry practices and potential founder effects, these
values do not necessarily reflect the distribution of genotype
frequencies within other captive colonies or in wild rhesus monkey
populations. Nonetheless, the presence of allelic variation in the
rhesus TRIM5 gene can be exploited to study the impact of
TRIM5 expression in vivo.
Author Summary
The human immunodeficiency viruses HIV-1 and HIV-2
originated from cross-species transmission of simian
immunodeficiency viruses (SIVs) from chimpanzees
(SIVcpz) and sooty mangabeys (SIVsm), respectively. A
related virus, SIVmac, causes AIDS-like pathogenesis in
rhesus macaques; like HIV-2, SIVmac is the product of a
cross-species jump of SIVsm from sooty mangabeys. The
primate TRIM5 gene encodes a factor with potent antiviral
activity when tested in the laboratory, and TRIM5 proteins
are thought to play a role in restricting the movement of
viruses between species in nature. In this study, we show
that genetic variation in the TRIM5 gene of rhesus
macaques heavily influences the outcome of cross-species
transmission of SIVsm and that emergence of SIVmac in
rhesus macaques in the 1970s required adaptations to
circumvent the genetic barrier imposed by the rhesus
macaque TRIM5 gene. Our results confirm the hypothesis
that TRIM5 can influence the process of cross-species
transmission and emergence of viruses related to HIV-1
and HIV-2 and serve as a striking illustration of how host
genes can influence virus evolution.
Figure 1. The rhesus macaque TRIM5 coding sequence is highly polymorphic. Rhesus macaque TRIM5 proteins are distinguished by
polymorphic variation in the B30.2/SPRY domain (encoded by TRIM5
TFP and TRIM5
Q alleles), or by complete replacement of the B30.2/SPRY domain
with a CypA domain (encoded by the TRIM5
CypA allele). Shown are polymorphic sites that differentiate six common rhesus TRIM5 alleles, including
three TRIM5
TFP alleles (Mamu-1, Mamu-2, and Mamu-3), two TRIM5
Q alleles (Mamu-4, Mamu-5), and the TRIM5CypA allele. For more details, see
references [15,17]. Accession numbers for the depicted alleles are also available in GenBank as follows: Mamu-1 through Mamu-5 (EF113914–
EF113918); TRIM5CypA (EU359036).
doi:10.1371/journal.pbio.1000462.g001
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cross-species transmission and emergence of primate lentiviruses,
we tested six representative alleles of rhesus macaque TRIM5 for
restriction activity against four closely related viruses of old-world
monkeys, SIVmac239, SIVsmE543, SIVsmE041, and SIVstm/
37.16 (Table 1). SIVmac239 is a molecular clone of a highly
adapted, emergent virus of rhesus macaques [25], generated in the
1980s by experimental passage of SIV-positive plasma through a
series of five monkeys [26]. In all likelihood, SIVmac239 is
descended from a cross-species transmission event that took place
in the 1960s in captive colonies of rhesus macaques [5], probably
as the unintended consequence of experiments involving transfer
of biological material from SIVsm-positive sooty mangabeys to
rhesus macaques [27]. Regardless of origin, as a result of this long
association with macaques, experimental infection with SIV-
mac239 reproducibly results in high levels of persistent viral
replication [28]. In contrast, SIVsmE543-3 is a molecular clone
derived by intentional inoculation of a rhesus macaque with
plasma from an SIVsm-infected sooty mangabey, followed by
passage through one additional rhesus macaque [29]; thus,
opportunity for SIVsmE543-3 to adapt to macaques was limited
to only two animals. As a result, SIVsmE543-3 replication in
macaques is highly variable, with acute viral loads ranging from
10
3 to 10
8 viral RNA copies/ml plasma, and set-point values from
,100 to 10
8. Variation in SIVsmE543-3 infected animals is
consistent with an influence of genetic variation in a host gene or
genes [30]. SIVsmE041 is a biological isolate cultured directly
from an SIV-positive sooty mangabey [31] and has therefore not
experienced any prior adaption to rhesus macaques. SIVstm/
37.16 is an SIV isolate from a different species, the stump-tailed
macaque (M. arctoides), and represents an independent cross-species
transmission event involving transmission of SIVsm directly to M.
arctoides animals [3,27,32,33]. The relevant properties of these four
viruses are summarized in Table 1.
Infectivity of all four viruses was measured on cell lines stably
expressing six common alleles of rhesus macaque TRIM5,
including three TRIM5
TFP alleles, two TRIM5
Q alleles, and the
TRIM5
CypA allele (Figure 2). SIVmac239 was resistant to all six.
SIVsmE041, SIVsmE543, and SIVstm were also resistant to
TRIM5
Q but unlike SIVmac239 were sensitive to both TRIM5
CypA
alleles and TRIM5
TFP alleles (Figure 2B,C,D). Of the four SIV
strains tested, only SIVmac239 is the product of decades of
replication and spread in rhesus macaques. Thus, the comparison
suggests that sensitivity to TRIM5
TFP and TRIM5
CypA alleles
represents the ancestral phenotype and that emergence of SIVsm
(as SIVmac) in rhesus macaques required acquisition of adaptive
changes to overcome those particular types of alleles. In contrast,
the SIVsm variants that first invaded rhesus macaques were
probably inherently resistant to TRIM5
Q alleles.
To analyze the impact of TRIM5 variation on cross-species
transmission directly, we acquired samples from two independent
SIVsm/macaque cohorts. The smaller cohort consisted of four
sooty mangabeys and four rhesus macaques that had been
experimentally inoculated with SIVsmE041 [34]. Infection of
sooty mangabeys (natural hosts of SIVsm) resulted in ready take of
virus and persistent infection (unpublished data), whereas infection
of macaques resulted in a transient infection followed by a
decrease in viral replication to a point near or below the detection
limit (Figure 3). Using archived DNA, we determined that the four
macaques included three TRIM5
TFP/TFP homozygotes and one
TRIM5
TFP/CypA heterozygote. Thus, the alleles present in these
four animals were all of the same types that restricted SIVsmE041
in tissue culture (Figure 2B). In one animal, replication resurged
during the first year, reaching ,10
4 RNA copies/ml plasma
(Figure 3). Capsid sequences recovered from this animal revealed
the appearance of two fixed changes, R97S and V108A
(SIVmac239 numbering) at the late time point (Figure 3C). In
contrast, amplification and sequencing from acute infection, from
the SIVsmE041 inoculum, and from an infected sooty mangabey,
revealed only the ancestral states at both positions (R97 and V108)
(Figure 3B).
The second and larger cohort consisted of historical samples
from 44 SIVsmE543-3-infected rhesus macaques. Genotype
frequencies in this cohort were 30% TRIM5
TFP/TFP, 23%
TRIM5
TFP/Q, 26% TRIM5
TFP/CypA, 12% TRIM5
Q/Q,9 %
TRIM5
Q/CypA, and 0% TRIM5
CypA/CypA. Animals with two
restrictive alleles (TRIM5
TFP/TFP and TRIM5
TFP/CypA) had dra-
matically diminished viral replication compared to TRIM5
Q/Q
homozygotes, with mean (geometric) differences of 830-fold and
1,728-fold, respectively, by 8 wk post-infection (Figure 4). Animals
with one restrictive allele (TRIM5
TFP/Q and TRIM5
CypA/Q
heterozygotes) displayed intermediate levels of viral replication.
Taken in conjunction with the clear differences in restriction of
SIVsmE543-3 by TRIM5
TFP, TRIM5
CypA, and TRIM5
Q in vitro
(Figure 2C), these results are consistent with allelic variation in
TRIM5 having a significant impact on SIVsmE543 replication
kinetics in rhesus macaques. We also obtained archived DNA from
animal #E543, the source of the original SIVsmE543-3 clone
[29], and determined that this animal had been a TRIM5
Q/Q
homozygote. The fact that E543 bore a non-restrictive genotype
may well have facilitated isolation of the original SIVsmE543-3
clone.
Several reports describe a correlation between specific alleles of
class I MHC and enhanced control of SIVmac239/SIVmac251
infection in rhesus macaques [35–37]. Specifically, MHC class-I
Mamu-B*08 and Mamu-B*17 alleles have been associated with
lower levels of chronic phase viral replication in SIVmac239-
infected animals [35,37]. Several observations argue against the
Table 1. Overview of SIV strains used in this study.
Virus Passage History Phenotype in Rhesus Macaques Reference
SIVsmE041 primary sooty mangabey isolate low pathogenicity; variable viremia [31,34]
SIVsmE543-3 cloned after experimental passage of
SIVsm through two rhesus macaques
variable pathogenicity; variable viremia [29]
SIVmac239 descendant of SIVsm; history in rhesus
macaques uncertain (.10 y)
high pathogenicity; high viremia [25,27,28]
SIVstm/37.16 descendant of SIVsm; history in stump-tailed
macaques uncertain (.10 y)
unknown [32,33]
doi:10.1371/journal.pbio.1000462.t001
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macaques being due to Mhc class I rather than TRIM5. First, the
TRIM5 and class I MHC loci are on different chromosomes,
reducing the probability of a chance association between
suppressive alleles of TRIM5 and a specific allele or alleles of
class I MHC with activity against SIVsmE543-3. More impor-
tantly, the effects of class I Mhc on SIVmac239 replication do not
manifest during the acute stage of infection [38], whereas the
correlation with TRIM5 genotype is already apparent during acute
infection (Figure 4D). Finally, Goldstein et al. demonstrated that
variation in susceptibility of cells taken from naı ¨ve animals (prior to
infection) and tested ex vivo correlated with viral replication levels
in vivo, when the same animals were subsequently infected with
SIVsmE543; such results argue in favor of an inherent, genetic
cause of variation in susceptibility and against an effect of virus-
specific adaptive immune responses induced by infection [30].
Finally, we typed all 43 animals in the SIVsm543-3 cohort for the
presence of the Mamu-B*08 and Mamu-B*17 alleles and found no
association between these alleles and the observed differences in
Figure 4. Most importantly, none of the infected animals with
TRIM5
Q/Q or TRIM5
TFP/CypA genotypes were Mamu-B*08 or
Mamu-B*17 positive, so the statistically significant differences
between those two groups cannot be attributed to Mamu-B*08 or
Mamu-B*17 associated control of SIVsmE543. Thus, the observed
correlation between TRIM5 genotype and SIVsmE543-3 replica-
tion levels is not due to a spurious association between suppressive
alleles of TRIM5 and class I MHC alleles previously associated with
control of SIVmac239. It is important to note, however, that this
result does not rule out a general influence of class I Mhc on viral
replication levels in rhesus macaques, only that MHC genotype
does not explain the correlation depicted in Figure 4. Among other
things, allelic variation in MHC class I may well contribute to the
significant variation observed within groups (Figure 4C,D,E).
Three macaques in the SIVsmE543-3 cohort also had patterns
of resurgent viral replication consistent with escape from
suppression (Figure 5A). All three animals had two restrictive
alleles and included one TRIM5
TFP/TFP homozygote and two
TRIM5
TFP/CypA heterozygotes. We amplified gag sequences encod-
ing the NTD of CA from all three animals, and from a TRIM5
Q/Q
animal, and compared these to the original SIVsmE543-3 clone
(Figure 5B). Strikingly, an R97S change was present in every clone
from all three animals, typically due to an AGA-.AGC
substitution, although 3/15 clones in one animal were AGA-
.AGT. No changes were found in the corresponding region of
Figure 2. Differential restriction of SIVmac and SIVsm strains by multiple alleles of rhesus macaque TRIM5. Single-cycle infectivity was
measured on a panel of cell lines stably expressing six common alleles of rhesus TRIM5 [15,17]. Alleles tested included three TRIM5
TFP (Mamu-1,
Mamu-2, Mamu-3, dark blue bars), two TRIM5
Q (Mamu-4 and Mamu-5, light blue bars), and TRIM5CypA (orange bars). Control cells stably expressing
the empty vector served as a negative control (black bars). Of the four closely related SIVs, only the rhesus macaque isolate SIVmac239 is resistant to
multiple alleles. Infectivity (% GFP-positive cells) was measured by flow-cytometry (error bars indicate 6 SEM). Virus stocks were first titered by serial
dilution on parental cells and normalized (Figure S1). Stable cell lines were generated from CRFK cells as described in the Materials and Methods
section. HIV-1NL4-3 was used as a positive control to confirm expression and function of the TRIM5
Q/Q alleles. (A) SIVmac239; (B) SIVsmE041; (C)
SIVsmE543-3; (D) SIVstm37/13; (E) HIV-1NL4-3; (F) Immunoblot confirming expression of HA-tagged TRIM5 proteins in cell lysates. upper panel, TRIM5
proteins; lower panel, b-actin loading control. Lanes: (1) Mamu-1; (2) Mamu-2; (3) Mamu-3; (4) Mamu-4; (5) Mamu-5; M, protein standard; TC,
TRIM5CypA; V, control cells expressing vector-only. GenBank accession number for the SIVsmE041 clone: HM059825.
doi:10.1371/journal.pbio.1000462.g002
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Q/Q animal. Thus, an
identical R97S change appeared independently in four animals
with suppressive TRIM5 genotypes, including three SIVsmE543-
infected animals (Figure 5B) and one SIVsmE041-infected animal
(Figure 3).
Phylogenetic analyses are consistent with a minimum of two
historical transmissions of SIVsm into macaques, one into stump-
tailed macaques (SIVstm), and the other into rhesus macaques
(SIVmac); both transmissions are thought to have occurred in
captive macaques sometime prior to the 1970s [3]. If TRIM5-
mediated restriction influences cross-species transmission of
primate lentiviruses, we predict the existence of adaptive changes
in SIV isolates corresponding to such events. Indeed, alignment of
the NTD of several lentiviruses in the SIVsm/SIVmac/HIV-2
lineage revealed multiple potential adaptations in SIVmac
(Figure 6). Most striking is an inferred R97S change, identical to
the change that appeared in the SIVsmE041 and SIVsmE543
experimental cohorts described above (Figures 3 and 5B). Based
on phylogeny of the SIVsm/SIVmac/HIV-2 lineage [3], the
R97S change was probably selected twice, once coinciding with
emergence of SIVmac in rhesus macaques and once coinciding
with emergence of SIVstm in stump-tailed macaques. Consistent
with this interpretation, the underlying nucleotide substitutions are
different in the two viruses (AGA-.AGC in SIVstm, and AGA-
.TCA in SIVmac). However, S97 is also found in a small
percentage of HIV-2 and SIVsm isolates; thus, it is possible that
one or both historical transmissions were initiated by an SIVsm
with serine at position 97, rather than de novo mutation as seen in
the experimental cohorts. In either case, these combined
observations strongly suggest that S97 is selectively advantageous
in macaques.
The second putative adaptation is a highly unusual LPA/QQ
substitution at the tip of the CA 4–5 loop (QQ
89,90 in SIVmac239).
How this change was generated is unclear but must have involved
multiple point mutations and a net loss of three nucleotides. While
QQ
89,90 is very common among SIVmac isolates, P
90 (the proline
in LPA
89–91) is extremely well conserved in SIVsm and HIV-2
isolates (Figure 6). The highly unusual nature of the LPA-.QQ
substitution, together with its location in a stretch of residues
known to affect TRIM5-mediated restriction [14,39], mark it as a
potential adaptation that arose to circumvent restriction by rhesus
macaque TRIM5 proteins.
To ask whether the R97S and LPA/QQ changes in SIVmac
strains arose as adaptations to overcome rhesus TRIM5, we
reverted these sites to the ancestral sequence in the context of the
macaque-adapted strain SIVmac239. We then tested SIV-
mac239
S97R and SIVmac239
QQ-.LPA for gain-of-sensitivity to
different rhesus TRIM5 alleles. Indeed, the S97R reversion
resulted in increased sensitivity to all three TRIM5
TFP alleles but
had no effect on resistance to the TRIM5
Q or TRIM5CypA alleles.
In contrast, the QQ
89,90-to-LPA
89-91 reversion resulted in
sensitivity to both TRIM5
TFP and TRIM5CypA alleles. This closely
resembles the pattern displayed by SIVsm isolates (see Figure 2B
and C), confirming that these represent bona fide adaptations to
overcome restriction by rhesus TRIM5 alleles. Because QQ
89,90 is
in the 4–5 loop of capsid, the adaptation probably functions by
altering the TRIM5CypA binding site. The structural basis for the
interaction between the TRIM5 B30.2/SPRY domain and viral
CA is not yet well defined, and it is not clear why QQ
89,90 also
affects resistance to TRIM5
TFP alleles. However, this result is
consistent with studies showing that site-directed mutations in the
HIV-1 CypA-binding domain influence binding and restriction by
TRIM5a proteins [39]. A better understanding of the influence of
CA positions 89–91 on restriction awaits more detailed, structural
understanding of the interaction between CA and TRIM5a.
Neither reversion affected resistance of SIVmac239 to TRIM5
Q,
consistent with our observation that SIVsmE041 and SIVsmE543,
which retain ancestral states at these sites, were also resistant to
TRIM5
Q (Figure 2). We conclude that TRIM5
Q alleles did not
significantly hamper SIVsm colonization of rhesus macaques or its
emergence as SIVmac in the 1970s. In fact, TRIM5
Q/Q animals
may have facilitated initial transmission of SIVsm among
macaques, permitting higher levels of replication and increasing
the probability of adaptation and spread.
Unlike the R97S change, we did not see the LPA
89–91/QQ
89,90
change appear in either experimental cohort (Figures 3 and 5B),
possibly because the multiple mutations involved make it a low
probability occurrence. Once virus with the QQ
89,90 motif in CA
appeared, however, it probably contributed to emergence of
SIVmac by facilitating spread among animals bearing restrictive
TRIM5
CypA alleles. Consistent with this hypothesis, experimental
Figure 3. Attenuated replication of the sooty mangabey virus
SIVsmE041 upon experimental cross-species transmission to
rhesus macaques. The cohort was described previously [34]; briefly,
four Indian-origin rhesus macaques were inoculated intravenously with
25 ng p27 equivalent of an SIVsmE041 virus stock derived by co-culture
of cells from SIV-infected sooty mangabey #E041 on PBMC from a
second, SIV-negative sooty mangabey. Viral RNA levels in plasma (y-
axis) were determined by quantitative RT-PCR at different time-points
post-infection (x-axis). All four rhesus macaques displayed post-acute
reduction of viral replication by several orders of magnitude. Genotypes
were TRIM5
TFP/TFP (3 animals, green lines) and TRIM5
TFP/CypA (one
animal, black line). The three homozygotes had acute viral RNA levels
peaking between 10
5 and 10
6 (RNA copy equivalents/ml of plasma),
whereas the heterozygote had the lowest acute viral RNA levels
(2.3610
4 RNA copy eqs/ml). Viral replication rebounded in one of the
TRIM5
TFP/TFP animals (black arrow), suggestive of adaptation and escape.
(A) Viral RNA levels in plasma. (B) Partial sequencing of the region
encoding the N-terminal domain of the viral capsid from the indicated
animal (black arrow), using samples collected during acute infection. (C)
Partial sequencing of the region encoding the N-terminal domain of the
viral capsid from the indicated animal (black arrow) using samples
collected during week 89 post-infection. Comparison of (B) and (C)
revealed potential adaptive changes at amino-acid positions 97 and 108
(SIVmac239 numbering).
doi:10.1371/journal.pbio.1000462.g003
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89,90 sequence at the homologous positions
in the sooty mangabey strain SIVsmE041 by site-directed
mutagenesis rendered the virus resistant to TRIM5CypA
(Figure 6). The mutation did not affect sensitivity to TRIM5
TFP
alleles or resistance to TRIM5
Q alleles. Thus, reversion to the
ancestral state in SIVmac239 (changing QQ
89,90 to LPA
89–91)
resulted in sensitivity to restriction by TRIM5CypA, and the
reciprocal substitution to recreate the evolutionarily derived state
in SIVsmE041 (IPA to QQ) resulted in resistance to TRIM5-
CypA. These results are consistent with the hypothesis that the
QQ
89,90 sequence is an adaptation to overcome rhesus TRIM5-
CypA that arose during emergence of the SIVmac lineage. In the
case of SIVmac239
QQ/LPA, the reversion also affected resistance to
TRIM5
TFP alleles, suggesting that the effects of the adaptation may be
influenced by additional differences between the SIVsm and SIVmac
capsids. Finally, note that two mutants, SIVsmE041
IPA-.QQ and
SIVmac239
S97R, have similar patterns of restriction (compare
Figure 6B and 6D), consistent with the fact that these two viruses
are identical at the two sites in question (i.e., both viruses are QQ
89,90
and R
97).
Discussion
Host-encoded, dominant-acting blocks to retroviral infection, or
restriction factors (RF), were first defined genetically for murine and
avian retroviruses more than 40 years ago [40]. Over the last decade,
experiments seeking the causes of defined cellular blocks to HIV-1
infection uncovered three new RF genes, APOBEC3G (now
considered to be the prototype of a cluster of ,8 APOBEC3 genes),
TRIM5,a n dTetherin [11,41,42]. Consistent with the notion that these
genes played a role in protecting host organisms from retroviral
infections during the course of mammalian evolution, Tetherin,
APOBEC3G,a n dTRIM5 display signs of long-term positive selection,
including high levels of amino-acid diversification between closely
related species [9,43–46]. It is generally assumed that RF genes such
as TRIM5, APOBEC3G,a n dTetherin influence the distribution and
spread of viruses between hosts, with viral epidemics resulting in
selectivesweeps of these loci, and successful viruses in turnadapting to
the spectrum of restriction encoded by each host species [47]. Our
results provide direct evidence that expression of one of these factors
(TRIM5) can indeed suppress viral replication during the early stages
Figure 4. TRIM5 genotype and replication of SIVsmE543-3 in rhesus macaques. Archived samples were obtained from 43 Indian origin
rhesus macaques that had been infected intravenously (n=35) or intrarectally (n=9) with SIVsmE543-3 (TCID 50% from 1 to 1,000). None of the
animals were treated or vaccinated prior to infection. Genomic DNA extracted from stored PBMC was used to determine TRIM5 genotype. Data are
color-coded by genotype, as follows: red, TRIM5
Q/Q; orange, TRIM5
Q/CypA; blue, TRIM5
TFP/Q; green, TRIM5
TFP/TFP; and black, TRIM5
TFP/CypA. (A) Viral
replication (RNA copy equivalents per milliliter of plasma) through 12 wk post-infection; (B) Same data presented as geometric mean values for each
genotype; (C) area under the curve; (D) acute infection (defined as peak viremia for each animal during the first 4 wk post-infection); (E) 8 wk post-
infection. Viral replication levels were compared by non-parametric one-way ANOVA (Kruskal-Wallis test) with Dunn’s post-test. Pairs of groups that
differed significantly are indicated (p,0.01 or p,0.001).
doi:10.1371/journal.pbio.1000462.g004
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emergence and pathogenesis in the new host species requires
adaptation to overcome restriction. Given overall similarities in
evolutionary patterns and biological function, it seems very likely that
the APOBEC3 enzymes and Tetherin/BST2 will also be found to
influence patterns of cross-species transmission and viral emergence
among extant species.
In this study, we specifically demonstrated that the RF gene
TRIM5 can suppress replication of a primate immunodeficiency
virus in vivo at the time of cross-species transmission, and that
TRIM5-mediated suppression of viral replication selects for
acquisition of adaptive changes in the viral capsid protein. The
data included retrospective genotyping of two independent, cross-
species transmission cohorts, identification of at least two
adaptations selected for resistance to TRIM5 during emergence
of the SIVmac lineage, and functional assessment of allele-specific
restriction in cell-culture. While the adaptations in SIVmac239
capsid identified here (R
97S and LPA
89–91/QQ
89,90) have a direct
effect on restriction sensitivity, the modification of the otherwise
highly conserved residues R97 and P90 may well have required
additional adaptive adjustments elsewhere in the CA or the Gag
polyprotein. Identifying such changes, if they exist, will require
systematic testing of combinations of residues that vary between
the SIVmac and SIVsm lineages for impact on relative infectivity
in the presence and absence of TRIM5 expression.
The transmission event(s) leading to spread and emergence of
SIVsm in the U.S. macaque colonies have not been identified,
although there is indirect evidence suggesting that transmission
may have resulted from experimental procedures involving the
transfusion of material from one species into another [27].
Regardless of the mechanism(s) of initial transmission, our data
strongly suggest that adaptation to overcome restriction by a
specific subset of rhesus macaque TRIM5 alleles played a key role
in spread of SIVsm and its emergence as SIVmac in captive
colonies of rhesus macaques. Based on cell-culture assays, analysis
of experimental cohorts, and functional identification of adaptive
changes in the SIVmac239 capsid, we propose a simple but likely
scenario for the influence of variation in the rhesus macaque
TRIM5 gene on emergence of SIVmac in the U.S. National
Primate Research Center macaque colonies (Figure 7). Briefly, at
the time of initial cross-species exposure, we believe that the
SIVsm source was likely to be sensitive to restriction by a subset
of rhesus macaque TRIM5 alleles, including those with a TFP
sequence at residues 339–341 in the B30.2/SPRY domain
(TRIM5
TFP) and those that produce a TRIM5CypA chimera by
alternative splicing (TRIM5
CypA). In contrast, we have yet to
identify an SIV strain that is sensitive to alleles with a Q at
position 339 (TRIM5
Q); thus, it seems likely that animals bearing
TRIM5
Q alleles (particularly TRIM5
Q/Q homozygotes) permitted
initial spread and adaptation of SIVsm to rhesus macaques,
potentially facilitating acquisition of adaptations to overcome
other, as yet unidentified genetic barriers encountered in the
newly invaded host species. The appearance of the R-to-S and
the LPA-to-QQ changes in CA would have opened the way for
the virus to spread to a larger percentage of the macaque
population, ultimately leading to emergence of pathogenic
SIVmac.
None of the viruses tested in this study except HIV-1 were
sensitive to the rhesus macaque TRIM5
Q alleles. It is noteworthy
that all known human alleles of TRIM5 have a Q at the
homologous position, suggesting that human TRIM5 may not pose
a critical barrier to transmission of SIVsm into human
populations; in this regard, it would be interesting to assess the
ability of human TRIM5 variants to restrict divergent primary
isolates of SIVsm found in regions of endemic infection among
African nonhuman primates and to look for correlations between
TRIM5 and susceptibility to HIV-2 in human AIDS cohorts.
An unexpected finding from analysis of the experimental
transmission cohorts was the establishment of infection even in
animals with restrictive genotypes. In many cases,we found that once
animals with restrictive genotypes were infected, viral replication
often continued to be suppressed to low levels for many weeks
(Figure 4). In nature, lower viremia could reduce the probability that
the infected individual will pass the virus on to additional individuals
in the new host population, thus extending the role of TRIM5 in
preventing emergence beyond the initial cross-species transmission
Figure 5. Emergence of Trim5-resistant SIV in vivo. (A) Viral
replication suggestive of suppression followed by adaptation in three
animals, as indicated by a green line (TRIM5
TFP/TFP homozygote) and two
black lines (TRIM5
TFP/CypA heterozygotes). (B) Sequences encoding a
portion of the N-terminal region of CA were amplified, cloned, and
sequenced from all three animals, as well as from a TRIM5
Q/Q
homozygote with typical, high levels of persistent viral replication.
Also shown is the sequence of the SIVsmE543-3 clone. An R97S change
was present in every clone from the three animals with restrictive
genotypes, but not in the non-restrictive TRIM5
Q/Q control animal. At
the nucleotide level, both Arg(AGA)-to-Ser(AGC) and Arg(AGA)-to-
Ser(AGT) were seen. The aligned amino-acid sequences correspond to
residues 89–113 in the N-terminal domain of the SIVmac239 capsid;
however, SIVsmE543-3 has one additional amino-acid in this region
compared to SIVmac239, so that R97S actually appears at position 98 in
the depicted alignment.
doi:10.1371/journal.pbio.1000462.g005
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does not necessarily address the impact of TRIM5 during natural
exposure and transmission, and it is possiblethat the observed pattern
is, at least in part, the consequence of experimental routes of
transmission. For example, in many SIV/macaque studies, including
the cohorts analyzed here, high titer stocks of virus (TCID50 in the
range of 1 to 1,000) are used to initiate infections by intravenous
injection. Since the effect of restriction by TRIM5a is known to be
saturable, it is possible that a large bolus of localized infection
manages to initially swamp out restriction and permits virus to seed a
Figure 6. Adaptations in the CA of SIVmac strains confer resistance to a subset of rhesus TRIM5 alleles. (A) Partial alignment of the NTD
of CA from multiple primate lentiviruses highlights the unusual QQ
89,90 sequence at the tip of the CypA-binding loop, which is unique to the SIVmac
lineage. Also shown is an inferred change at position 97 at the base of the loop (in helix 5), identical to the R97S change that arose in the SIVsm
experimental cohorts shown in Figures 2 and 3. (B) Location of LPA
89–91 and R
97 on the HIV-2 CA crystal structure, highlighted in red (structure is from
reference [23]). (C) Infectivity of parental SIVmac239; bars are color-coded as described in the legend of Figure 2. (D) Infectivity of SIVmac239
S97R,i n
which S97 has been reverted to the ancestral R97, reveals a gain of sensitivity to TRIM5
TFP alleles (dark blue bars). (E) Infectivity of SIVmac239
QQ/LPA (in
which QQ
89,90 has been reverted to the ancestral LPA
89–91) reveals a gain of sensitivity to TRIM5
TFP alleles (dark blue bars) and TRIM5
CypA (orange bars).
(F) Changing the ancestral IPA to QQ in SIVsmE041 (SIVsmE041
IPA/QQ) results in a gain of resistance to TRIM5CypA.
doi:10.1371/journal.pbio.1000462.g006
Figure 7. Scenario depicting the inferred role of rhesus macaque TRIM5 in emergence of SIV in captive Asian macaque colonies in
the late 20th century. Colored circles represent hypothetical populations of sooty mangabey monkeys (red circle) and rhesus macaques (blue
circle). In this scenario, at the time of transmission, SIVsm was initially resistant to rhesus TRIM5
Q alleles but sensitive to alleles of the TRIM5
TFP and
TRIM5
CypA types. Initially (1), Infection of animals bearing TRIM5
Q alleles (particularly TRIM5
Q/Q animals) permitted high-titer, persistent infection, and
the greatest potential for further transmission in the new host species. Replication in these animals also provided opportunity for adaptation to the
new host. Subsequently (2), the appearance of adaptive changes in the N-terminal domain of the viral capsid protein (including S
97 and QQ
89,90)
allowed viral replication in a larger percentage of the population and ultimately facilitated emergence of pathogenic SIVmac.
doi:10.1371/journal.pbio.1000462.g007
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infection. In this regard, experimental intravenous infection of
macaques may more closely resemble accidental human exposure to
HIV-1 via blood-transfusion or contaminated, hypodermic syringes.
It is possible that the effect of TRIM5 could be greater under
conditions of natural exposure to virus, such as through sexual
contact or fighting; however, we are currently unaware of any studies
that address this issue. In recent years, many SIV/AIDS vaccine
studies have incorporated low-dose mucosal challenges, to more
closely mimic the conditions of sexual transmission. Under such
conditions, it is possible that the effect of TRIM5 genotype on
infection will be even more pronounced. Just as historical samples
were used for this study, genotyping of appropriate archived samples
from completed or ongoing SIV/vaccine studies may also prove
useful for evaluating the interactions between TRIM5 genotype, viral
dose, and route of transmission.
Alternatively, there are published reports indicating that TRIM5
gene expression is interferon-regulated [48,49]; thus, it is also
possible that the full impact of TRIM5 on viral replication in vivo is
not manifest until after the first round of infection is well underway.
Such a pattern is consistent with the observation that the impact of
TRIM5 genotype in the SIVsmE543-3 infected animals appeared to
persist during the weeks following acute infection (Figure 4). The
TRIM5 gene is also known to encode multiple splice-isoforms [50],
including mRNA molecules lacking viral specificity encoded by a
B30.2/SPRY or CypA domain; however, it is not known whether
these are differentially expressed in vivo in response to infection or
whether patterns of isoform expression differ between tissues. In
vivo studies will be required to determine how TRIM5 is regulated,
whether regulation changes in response to viral infection, and to
identify the patterns of TRIM5 expression in cell types responsible
for initial infection and spread in vivo.
The impact of variation in rhesus macaque TRIM5 has practical
implicationsforpreclinicalAIDSvaccine research.SIVsmE543and
the related SIVsmE660 serve as heterologous challenge strains for
widely used SIVmac239-derived vaccine immunogens in rhesus
macaques [38,51–54]. The pronounced effect of TRIM5 variation
on SIVsmE543 infection is likely to confound comparison of
vaccinated and control groups, particularly if they are not balanced
for restrictive and permissive alleles; this may be especially true for
studies with typically small numbers of animals (n=4–6) in each
group. This may also be true of SIV strains not examined here, and
possibly extends to other SIV/AIDS model organisms including
Chinese-origin rhesus macaques and other commonly studied
Macaca species, such as M. nemestrina and M. fascicularis. Moreover,
vaccines expressing Gag, the target of TRIM5, may be affected by
TRIM5 genotype. This is potentially the case for live-attenuated
SIV, where vaccine efficacy is influenced by the degree to which the
vaccine strain replicates in the inoculated animal [55]. Finally, as
discussed above, the potential effects of viral dose or route of
transmission on restriction by TRIM5 remain to be determined.
TRIM5variationand susceptibility to infectionhasbeenexplored
in candidate gene studies in HIV/AIDS cohorts, although reported
associations were weak [56–59]. Recently, a modest but significant
association between TRIM5 genotype and infection in a cohort of
SIVmac251-infected macaques was described [24]. While the SIV
study did not correlate individual TRIM5 polymorphisms with viral
replication levels, we note that all haplotypes associated with lower
viremia in that report were of the TRIM5
TFP class (TRIM5
CypA was
excluded from their analysis) [24]. The magnitude of the effect on
SIVmac251 (1.3 log) was smaller than we observed with
SIVsmE543 or SIVsmE041 (,2.0 to 3.0 log). This is consistent
with the fact that SIVmac251, like its derivative SIVmac239, is the
product of years of adaptation in rhesus macaques, while
SIVsmE543 and SIVsmE041 have had little or no opportunity,
respectively, to adapt to this species [25,29,31]. Similarly, lack of a
strong association between TRIM5 variation and infection in HIV/
AIDS cohorts may be due to limited variation in human TRIM5
and the fact that HIV-1 has been spreading in human populations
for decades [60,61]. Our results, particularly when taken in light of
the results from HIV/AIDS cohorts and the SIVmac251 cohort,
support the conclusion that TRIM5 primarily governs the
transmission of viruses between genetically distinct populations or
species and further suggest that the impact of restriction can
diminish as a virus spreads and adapts to a new host population.
Methods
Ethics Statement
All analyses were performed using archived material, and none
of the analyses described involved new animal experiments.
Animals at the New England Primate Research Center (NEPRC)
were maintained in accordance with standards of the Association
for Assessment and Accreditation of Laboratory Animal Care and
the Harvard Medical School Animal Care and Use Committee.
Animal experiments were approved by the Harvard Medical Area
Standing Committee on Animals and conducted according to the
principles described in the Guide for the Care and Use of
Laboratory Animals. All animals at the NIH were housed in
accordance with American Association for Accreditation of
Laboratory Animal Care standards, and the NIH investigators
adhered to the Guide for the Care and Use of Laboratory Animals
prepared by the Committee on Care and Use of Laboratory
Animals of the Institute of Laboratory Resources, National
Resource Council, and the NIAID Animal Care and Use
Committee-approved protocols.
Plasmids
The SIVmac239-based retroviral vector V1EGFP (gift from
Hung Fan, University of California, Irvine, CA) was modified to
contain a functional gag-pol ORF. The NarI and SphI sites were
used to replace SIVmac239 sequence with that of SIVsmE543
(pGEM-E543 was a gift from Vanessa Hirsch, NIAID, Bethesda,
MD). For this purpose the SphI site was introduced by PCR
(forward: 59-CCTAGCAGGTTGGCGCCTGAACAGG-39, re-
verse: 59-GTTATAGCATGCCTCTAGAGGGCGG-39). A 59
half of SIVsmE041 was synthesized by GENEART (Regensburg,
Germany) with the sequence based on a consensus of sequences
obtained by A.K. and S.O. The fragment was engineered to
contain NarI and SphI sites for subcloning into V1EGFP.
SIVstm/37.16 (gift from Frank Novembre, Emory University,
Atlanta, GA) was used for subcloning the SIVstm gag into
V1EGFP using the NarI and SbfI sites.
Primary Cells and Cell Lines
Primary Blood Mononucleated Cells (PBMC) were isolated
from heparin- or EDTA-treated rhesus macaque blood samples by
density centrifugation with Lymphocyte Separation Medium.
PBMC were activated with RPMI/10% FBS containing 50 IU/
ml phytohaemagglutinin or 5 mg/ml Concanavalin A for 2 d;
afterwards cells were maintained in R10 supplemented with
50 IU/ml interleukin-2.
Crandell-Rees Feline Kidney (CRFK) cells as well as Human
Embryonic Kidney 293T/17 (HEK293T/17) cells were obtained
from American Type Culture Collection (Manassas, VA) and
grown in DMEM/10% FBS. Generation of stable CRFK cell lines
was done as previously described in Newman et al., PNAS 103(50),
2006 [15]. For the experiments performed here, new stable CRFK
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TRIM5 alleles. For this purpose an HA tag was added by PCR
(forward: 59-GCGGCCGCATGGCTTCTGGAATC-39; reverse:
59-CCACCGGTGGCTCAAGCGTAGTCTGGGACGTCGTA-
TGGGTAGCCGCCAGAGCTTGGTGAGCACAGAG-39) and
the NotI and AgeI sites were used for subcloning into pQCXIN
(BD Biosciences, Franklin Lakes, NJ). Stable cell lines were
maintained in DMEM/10% FBS supplemented with 0.5 mg/ml
G418. All cultured cells were maintained at 37uC with 5% CO2.
Viruses
All single-cycle SIV viruses were produced in HEK293T/17
cells by cotransfection of the appropriate V1EGFP-SIV plasmid
and pVSV-G (Clontech Laboratories, Mountain View, CA), using
the GenJet transfection system (SignaGen; Ijamsville, MD). The
single-cycle HIV-1 virus stock was made by cotransfection of
pNL43DenvGFP and pVSV-G. Single-cycle HIV-2 was made by
cotransfection of pHIV-2(ROD)GFP and pVSV-G. Culture
supernatants containing the single-cycle, GFP/EGFP expressing,
VSV-G-pseudotyped virions were titered on untransfected CRFK
cells; supernatant volumes resulting in approximately 30% GFP/
EGFP
+ CRFK cells were used for infectivity assays on the stably
transfected cell lines expressing the various rhesus TRIM5 alleles.
Infectivity Assays
Stable CRFK cells were seeded at a concentration of 5610
4
cells per well in 12-well-plates and infected with the appropriate
amount of VSV-G pseudotyped, single-cycle, GFP/EGFP ex-
pressing viruses. All infections were done in triplicate. After 3 d,
expression of GFP/EGFP was analyzed by fluorescence-activated
cell sorting (FACS) performed on a FACSCalibur
TM flow
cytometer (BD, Franklin Lakes, NJ), and data were analyzed
using FlowJo (Tree Star, Inc., Ashland, OR).
PCR (Site-Directed Mutagenesis, Genotyping,
Sequencing)
The Q
89Q
90 to LPA and S97R mutants of SIVmac239 capsid
were made by site-directed mutagenesis on a SIVmac239 59
plasmid (Q
89Q
90 to LPA: forward: 59-GCAGATTGGGACTTG-
CAGCACCCAATACCAGGCCCCTTACCAGCGGGACAA-
CTTAGGGAGCCGTCAGG-39; reverse: 59CCTGACGGCT-
CCCTAAGTTCTCCCGCTGGTAAGGGGCCTGGTATTGG-
GTGCTGCAAGTCCCAATCTGC-39) (S97R: forward: 59-CCC-
ACAACCAGCTCCACAACAAGGACAACTTAGGGAGCCG-
AGGGGATCAGATATTGCAGGAAC-39; reverse: 59-GTTCC-
TGCAATATCTGATCCCCTCGGCTCCCTAAGTTCTCCT-
TCTTCTGGAGCTGGTTGTGGG-39).
The IPA-to-Q
89Q
90 mutants of SIVsmE041 were made by site-
directed mutagenesis on a SIVsmE041 59 plasmid (IPA-to-QQ:
forward: 59-CCACAGCCAGGTCCACAACAAGGACAACT-
TAGAGACCCGAGAGG-39; reverse: 59-CCTCTCGGGTCT-
CTAAGTTGTCCTTGTTGTGGACCTGGCTGTGG-39). For
all mutants, NarI and SphI sites were used for subcloning into
V1EGFP.
TRIM5 genotypes of rhesus macaques were determined by
isolation of genomic DNA from PBMC using the QIAamp DNA
Blood Mini kit (QIAGEN, Valencia, CA) and direct sequencing of
a PCR fragment (forward: 59-CAGTGCTGACTCCTTTG-
CTTG-39; reverse: 59-GCTTCCCTGATGTGATAC-39) of the
C-terminal B30.2/SPRY domain of TRIM5. The following PCR
protocol was implemented: 1 min at 94uC initial denaturation,
15 s at 94uC denaturation, 30 s at 55uC annealing, 1 min at 68uC
extension, 10 min at 68uC final extension; steps 2 through 4 were
repeated for 30 cycles. PCR fragments were sequenced by
Retrogen (San Diego, CA) and data were analyzed with the
Codoncode software (Codoncode Corporation, Dedham, MA).
Viral RNA was extracted from blood plasma with the High
Pure Viral RNA kit (Roche Diagnostics Corporation, Indianapo-
lis, IN) and partial capsid sequence was determined by direct
sequencing of an RT-PCR fragment (forward: 59-GAAGCTTGC-
CACCATGGGCGCGAGAAACTC-39; reverse: 59-CCTCTCT-
GTTGGACTGCTGC-39).
Immunoblotting
Stable CRFK cells expressing the various HA-tagged TRIM5
alleles were seeded at a density of 5610
4 cells per well in a 6-well-
plate. After 48 h, cells were lysed in M-PER reagent (Pierce
Biotechnology, Rockford, IL), and total protein concentration of
each lysate was determined by measurement of A280 with a
NanoDrop spectrophotometer (Thermo Fisher Scientific, Wal-
tham, MA). Equal amounts of total protein were separated by
SDS/PAGE and HA-tagged TRIM5 proteins were detected with
rat monoclonal Anti-HA-Peroxidase High Affinity antibody
(Roche Diagnostics Corporation, Indianapolis, IN). b-actin was
detected with mouse monoclonal beta Actin-HRP antibody
(Abcam Inc., Cambridge, MA).
Experimental Infections
Forty-four rhesus macaques of Indian origin were infected with
SIVsmE543-3 either intravenously (n=35) or intrarectally (n=9)
with a TCID 50% ranging from 1 to 1,000. There was no
statistically significant difference in viral RNA levels relative to
route of inoculation (unpublished data). None of the animals were
treated or vaccinated prior to infection. The majority of the
animals (n=41) were inoculated with a cell-free virus stock
generated by infection of pigtailed macaque PBMC with virus
produced by transfection of CEMx174 cells with the SIVsmE543-
3 molecular clone.
Blood Plasma Viral Loads
The quantification of plasma viral loads was described
previously in Hirsch et al. [29]. Briefly, viral RNA loads were
determined by real-time reverse transcriptase-PCR (RT-PCR).
For this purpose, viral RNA from plasma was serially diluted and
used as a template in a RT-PCR reaction, together with known
amounts of pSG83 as an internal control template. Results were
normalized to the volume of plasma extracted and expressed as
SIV RNA copies per milliliter of plasma.
Supporting Information
Figure S1 Production of VSV-G pseudotyped, single-
cycle SIV for restriction assays. (A) The modified V1EGFP
vector, as described in Methods. (B) pVSV-G vector. (C) Single
cycle SIVmac239 titration on parental CRFK cells (TRIM5-null).
(D) Single-cycle SIVmac239QQ-.LPA. (E) Single cycle SIV-
mac239S-.R. (F) Single cycle SIVsmE543-3. (G) Single-cycle
SIVsmE041. Virions were produced by transient co-transfection of
a vector expressing viral proteins (A) and a second vector
expressing the Vesicular Stomatitis Virus G-protein (B). The viral
vector also produces messenger RNA containing a transducible
enhanced Green Fluroescent Protein (eGFP) ORF in place of the
viral nef gene (green box); in the subsequent round of infection, the
reporter RNA is reverse transcribed and integrated into the
infected cell. Infection is then monitored by flow-cytometry to
count eGFP-positive cells as a percent of total live cells (C–G).
Found at: doi:10.1371/journal.pbio.1000462.s001 (8.33 MB TIF)
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